There are >10,000 species of venomous marine snails belonging to the superfamily Conoidea;one group in the superfamily are the cone snails (Conus). The general goal of this program is to develop highly selective peptide ligands derived from Conoidean venoms that have novel pharmacological specificity for various ion channel and receptor subtypes. Our laboratories have previously isolated such peptides from Conus venoms, and these have been used extensively in basic research by many laboratories, and important translational applications have emerged. In particular, Conus peptides have uncovered novel mechanisms to alleviate pain. A general goal of this Program is to develop highly selective peptide ligands for novel targets. In the next grant period, we plan to expand the general biological resource to be accessed, from the venoms of the 700 cone snails to the venomous snails in the entire family of Conoidea. The discovery activities of this Program follow a cladistic strategy that was convincingly validated in the last grant period. We believe that this discovery strategy represents a potential paradigm shift in how discovery of lead compounds from animal biodiversity will be carried out in the future. The cladistic discovery strategy is more systematic, science based and efficient than the usual procedures for """"""""bioprospecting"""""""". The Program is organized into four Cores and four Projects. Together, the Cores support all of the discovery activities of this Program, including a significant number of discovery initiatives that are not supported by any of the Projects. Furthermore, the Cores will also strengthen the scientific foundation required for extending the cladistic discovery strategy to all groups in the superfamily Conoidea. The goals of the Projects are to develop panels of highly subtype-specific peptide ligands for the nicotinic receptor family, for the sodium channel family, for the G-protein coupled-peptide receptor family, and for K channels. Each project also has specific translational applications, including the development of analgesic compounds for pain and cardioprotective compounds for myocardial infarction due to ischemia. An experimental plan to clarify basic mechanisms that underlie each translational application will be pursued. This discovery program has led to one compound already approved as a commercial drug, and many others that have either reached human clinical trials or are in advanced preclinical development. The cladistic strategy to be employed, and the larger biological resource to be accessed, should greatly accelerate the pace of discovery ultimately leading to novel translational applications. Thus, the research activities of this program interact broadly with the basic research community studying ion channels and receptors, as well as the more clinically oriented community developing novel therapeutic and diagnostic applications.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Program Projects (P01)
Project #
5P01GM048677-19
Application #
8145714
Study Section
Special Emphasis Panel (ZRG1-MDCN-G (40))
Program Officer
Dunsmore, Sarah
Project Start
1997-01-01
Project End
2013-06-30
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
19
Fiscal Year
2011
Total Cost
$1,755,644
Indirect Cost
Name
University of Utah
Department
Biology
Type
Schools of Arts and Sciences
DUNS #
009095365
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Robinson, Samuel D; Li, Qing; Bandyopadhyay, Pradip K et al. (2017) Hormone-like peptides in the venoms of marine cone snails. Gen Comp Endocrinol 244:11-18
Backhaus, Sören; Zakrzewicz, Anna; Richter, Katrin et al. (2017) Surfactant inhibits ATP-induced release of interleukin-1? via nicotinic acetylcholine receptors. J Lipid Res 58:1055-1066
Robinson, Samuel D; Li, Qing; Lu, Aiping et al. (2017) The Venom Repertoire of Conus gloriamaris (Chemnitz, 1777), the Glory of the Sea. Mar Drugs 15:
Amati, Anca-Laura; Zakrzewicz, Anna; Siebers, Kathrin et al. (2017) Chemokines (CCL3, CCL4, and CCL5) Inhibit ATP-Induced Release of IL-1? by Monocytic Cells. Mediators Inflamm 2017:1434872
Hone, Arik J; McIntosh, J Michael (2017) Nicotinic acetylcholine receptors in neuropathic and inflammatory pain. FEBS Lett :
Hone, Arik J; Michael McIntosh, J; Rueda-Ruzafa, Lola et al. (2017) Therapeutic concentrations of varenicline in the presence of nicotine increase action potential firing in human adrenal chromaffin cells. J Neurochem 140:37-52
Romero, Haylie K; Christensen, Sean B; Di Cesare Mannelli, Lorenzo et al. (2017) Inhibition of ?9?10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain. Proc Natl Acad Sci U S A 114:E1825-E1832
Memon, Tosifa; Chase, Kevin; Leavitt, Lee S et al. (2017) TRPA1 expression levels and excitability brake by KV channels influence cold sensitivity of TRPA1-expressing neurons. Neuroscience 353:76-86
Li, Qing; Barghi, Neda; Lu, Aiping et al. (2017) Divergence of the Venom Exogene Repertoire in Two Sister Species of Turriconus. Genome Biol Evol 9:2211-2225
Estakhr, Jasem; Abazari, Danya; Frisby, Kaitlyn et al. (2017) Differential Control of Dopaminergic Excitability and Locomotion by Cholinergic Inputs in Mouse Substantia Nigra. Curr Biol 27:1900-1914.e4

Showing the most recent 10 out of 260 publications